ONS Annual Congress Heralds Start of Oncology Nursing Month

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty.

PITTSBURGH—The Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty. The celebration kicks off on Thursday, May 4, 2006, on Oncology Nursing Day, during the Opening Ceremony of the Society's 31st Annual Congress in Boston, Massachusetts, and continues until May 31, 2006.

Oncology Nursing Month has been designed to recognize oncology nurses, to educate the public about oncology nursing, to provide an opportunity for special educational events for oncology nurses, and to celebrate the accomplishments of oncology nurses. A brochure with tips on how to promote Oncology Nursing Month is available on the Society's website at www.ons.org.

Look for comprehensive coverage of oral presentations, lectures, and posters from the Society's 31st Annual Congress in upcoming issues of ONI.

Articles in this issue
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLC
ONS Annual Congress Heralds Start of Oncology Nursing Month
All-Star Panel Spells Out Onc Promises, Problems
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosis
ODAC Says No to Gemzar for Ovarian Ca
Experts See Oncology Reimbursements Headed Down, Hard Negotiations With Payers Lie Ahead
Femara Effective Even After Years of No Therapy
XMRV Retrovirus Found in Some Prostate Ca's
Taxotere Wins FDA Approval for Advanced Gastric Cancer
Community Oncology Practices Struggle to Cope With the Extra Requirements of Medicare Part D
Director of NCI Nominated as New FDA Commissioner
TAM-01 Finds Longer Tamoxifen Duration Is Not Better
Erbitux Wins Approval for Squamous Cell H&N Cancer
Young Doctors Are Hungry for Psychological Oncology Training
Posaconazole Reduces Serious IFIs in High-Risk Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

Russ Conroy
June 10th 2025
Article

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Russ Conroy
June 10th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma

Roman Fabbricatore
June 9th 2025
Article

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

Tim Cortese
June 9th 2025
Article

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.